RETL2 Activators
RETL2 Activators encompass a range of chemical entities that indirectly promote the functional activity of RETL2 by modulating distinct cellular signaling pathways. Forskolin and IBMX act to elevate intracellular cAMP levels, with Forskolin activating adenylyl cyclase and IBMX inhibiting phosphodiesterases to prevent cAMP degradation. The resulting increase in cAMP activates PKA, which may subsequently phosphorylate and activate RETL2 or relevant regulatory proteins, enhancing RETL2 activity. Similarly, PMA engages and activates PKC, which phosphorylates various substrates, potentially influencing RETL2 signaling pathways and leading to its functional activation. Concurrently, Sphingosine-1-phosphate activates S1P receptors that trigger PI3K/Akt signaling, a process that might culminate in RETL2 activation. Genistein contributes to this regulation by inhibiting tyrosine kinases, potentially reducing competition with RETL2 pathways and facilitating its functional enhancement.
In parallel, compounds like Epigallocatechin gallate (EGCG) and Staurosporine serve as kinase inhibitors, with the former potentially preventing kinases from negatively regulating RETL2, and the latter broadly inhibiting kinases that may suppress RETL2 signaling, thereby indirectly supporting RETL2 activation. LY294002 and U0126, through their inhibitory actions on PI3K and MEK1/2 respectively, alter downstream signaling that can shift the balance of kinase activity to favor RETL2 activation. Thapsigargin, by disrupting calcium homeostasis via SERCA inhibition, raises intracellular calcium levels, which can activate calcium-dependent signaling pathways enhancing RETL2 function. Similarly, A23187 acts as a calcium ionophore, leading to increased intracellular calcium and potential activation of calcium-mediated pathways linked to RETL2. Lastly, SB203580 specifically inhibits p38 MAPK, redirecting the signaling balance towards pathways that support the enhancement of RETL2's functional activity.
SEE ALSO...
Items 1 to 10 of 11 total
Display:
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Forskolin | 66575-29-9 | sc-3562 sc-3562A sc-3562B sc-3562C sc-3562D | 5 mg 50 mg 1 g 2 g 5 g | $78.00 $153.00 $740.00 $1413.00 $2091.00 | 73 | |
Forskolin activates adenylyl cyclase, resulting in increased production of cyclic AMP (cAMP). Elevated cAMP levels can enhance RETL2 activity by activating protein kinase A (PKA), which may phosphorylate RETL2 or associated regulatory proteins, leading to its activation. | ||||||
IBMX | 28822-58-4 | sc-201188 sc-201188B sc-201188A | 200 mg 500 mg 1 g | $260.00 $350.00 $500.00 | 34 | |
Isobutylmethylxanthine (IBMX) is a non-selective inhibitor of phosphodiesterases, preventing the breakdown of cAMP. The resulting increase in cAMP can enhance RETL2 activity indirectly through PKA-dependent pathways. | ||||||
PMA | 16561-29-8 | sc-3576 sc-3576A sc-3576B sc-3576C sc-3576D | 1 mg 5 mg 10 mg 25 mg 100 mg | $41.00 $132.00 $214.00 $500.00 $948.00 | 119 | |
Phorbol 12-myristate 13-acetate (PMA) activates protein kinase C (PKC), which can phosphorylate substrates that affect RETL2 signaling pathways, thus indirectly enhancing RETL2's functional activity. | ||||||
D-erythro-Sphingosine-1-phosphate | 26993-30-6 | sc-201383 sc-201383D sc-201383A sc-201383B sc-201383C | 1 mg 2 mg 5 mg 10 mg 25 mg | $165.00 $322.00 $570.00 $907.00 $1727.00 | 7 | |
Sphingosine-1-phosphate (S1P) engages S1P receptors, which can activate intracellular signaling cascades such as PI3K/Akt, potentially resulting in the activation of RETL2 through downstream effects on cellular processes. | ||||||
(−)-Epigallocatechin Gallate | 989-51-5 | sc-200802 sc-200802A sc-200802B sc-200802C sc-200802D sc-200802E | 10 mg 50 mg 100 mg 500 mg 1 g 10 g | $43.00 $73.00 $126.00 $243.00 $530.00 $1259.00 | 11 | |
EGCG is a kinase inhibitor that can modify signaling pathways by inhibiting kinases that negatively regulate RETL2, leading to an increase in RETL2's functional activity. | ||||||
LY 294002 | 154447-36-6 | sc-201426 sc-201426A | 5 mg 25 mg | $123.00 $400.00 | 148 | |
LY294002 is a PI3K inhibitor that may enhance RETL2 activity by altering signaling pathways downstream of PI3K, such as the Akt pathway, which can have regulatory effects on RETL2's function. | ||||||
Thapsigargin | 67526-95-8 | sc-24017 sc-24017A | 1 mg 5 mg | $136.00 $446.00 | 114 | |
Thapsigargin disrupts calcium homeostasis by inhibiting the sarcoplasmic/endoplasmic reticulum Ca2+ ATPase (SERCA). Elevated cytosolic calcium can activate signaling pathways that indirectly enhance the activity of RETL2. | ||||||
Genistein | 446-72-0 | sc-3515 sc-3515A sc-3515B sc-3515C sc-3515D sc-3515E sc-3515F | 100 mg 500 mg 1 g 5 g 10 g 25 g 100 g | $45.00 $164.00 $200.00 $402.00 $575.00 $981.00 $2031.00 | 46 | |
Genistein is a tyrosine kinase inhibitor that may enhance the activity of RETL2 by reducing competition from tyrosine kinase signaling, thereby favoring RETL2-associated pathways. | ||||||
Staurosporine | 62996-74-1 | sc-3510 sc-3510A sc-3510B | 100 µg 1 mg 5 mg | $82.00 $153.00 $396.00 | 113 | |
Staurosporine, as a broad-spectrum kinase inhibitor, can selectively enhance RETL2 activity by inhibiting kinases that negatively regulate RETL2 signaling pathways. | ||||||
A23187 | 52665-69-7 | sc-3591 sc-3591B sc-3591A sc-3591C | 1 mg 5 mg 10 mg 25 mg | $55.00 $131.00 $203.00 $317.00 | 23 | |
A23187 acts as a calcium ionophore, increasing intracellular calcium concentration and potentially activating calcium-dependent signaling pathways that enhance RETL2 activity. | ||||||